评TACTICS试验:TACE联合索拉非尼与单纯TACE在不可切除肝细胞癌中的对比研究  

Comment on the TACTICS Trial:A Comparative Study of TACE Combined With Sorafenib and TACE Alone in Hepatocellular Carcinoma

作　　者：陈双刚 范卫君[2] 杨翼帆 CHEN Shuang-gang;FAN Wei-jun;YANG Yi-fan(Department of Oncology,Yuebei People's Hospital,Shantou University Medical College,Guangdong Shaoguan 512028,China;Minimally Invasive Interventional Division,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;不详)

机构地区：[1]汕头大学附属粤北人民医院肿瘤内科,广东韶关512028 [2]中山大学肿瘤防治中心微创介入治疗科,广州510060 [3]广东省人民医院综合(介入)肿瘤一科,广州510080

出　　处：《循证医学》2021年第6期332-336,共5页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Kudo M,Ueshima K,Ikeda M,et al. Randomised,multicentre prospective trial of transarterial-chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. Gut,2020,69(8):1492-1501.

关 键 词：肝细胞癌 TACE 索拉非尼 不可切除 疗效 

分 类 号：R735.7[医药卫生—肿瘤]